ERC FUNDED PROJECTS

Prospective biosensing technologies will need to tackle the grand challenges arising from the global demographic changes. Among the most crucial tasks is the monitoring of food and environmental quality as well as the medical diagnosis. Digital fluidics offers vast advantages in performing these tasks relying on tiny containers with reacting biochemical species and allowing massively parallelized assays and high throughput screening using optical detection approaches. I envision that adding not-optical detectors, which electrically probe the analyte responses, will provide a source of new but complementary information, obtained in a label-free and contactless manner. Hence, these all-electric platforms enable monitoring the kinetics of chemical reactions in lab-on-chip format, as well as take over auxiliary tasks, e.g. indexing, counting of droplets, flow monitoring. In frame of the ERC project SMaRT, my team developed a unique detection platform -millifluidic resonance detector- that inductively couples to an analyte and assesses its physico-chemical properties. The unique selling points are (i) non-invasiveness to analyte, (ii) unnecessity of a transparent fluidic channel, (iii) cost efficiency and (iv) portability. Implementing the input from the partner companies, here I aim to reach the commercialization stage pursuing a number of key milestones, i.e. enhance the screening throughput, realize a platform independent of external electronic devices, provide a temperature stabilization of the response, and develop the app. Societal benefits: We demonstrated that the device provides an access to the metabolic activity of living organisms in droplets. This is way beyond the capabilities of the state-of-the-art optical detection. With this feature, the device can address the issue of increasing antibiotic resistance of bacteria and thus help to optimize the antibiotic policy in hospitals and households and to test new drugs in a time- and cost-efficient way.

150 000 €

Start date: 2017-09-01, End date: 2019-02-28

Liquid handling is an integral part of biological and medical assays. For many applications the method of choice is manual pipetting, which has significant limitations. Chiefly, it is user-time intensive and prone to sample handling issues (poor time accuracy and pipetting errors). While liquid handling robots do exist, they are expensive instruments, shared by many users and targeted for high-throughput applications. This leaves, in practice, most research and diagnostics without an automated solution. Here, we present an innovative solution to this problem: a compact and mobile automated liquid handling (AutoLiqHand) device for the individual user. This platform will enable to automate biomedical experiments and diagnostic routines which are currently done by hand. Moreover, its unique design enables it to run in a much larger range of biomedical settings than currently offered by existing solutions, and at the fraction of the cost. This platform was developed as part of the ERC-funded project SelfOrg and is routinely used in our lab for a variety of specialized and standard routines (e.g. drug treatment and immunostaining). The AutoLiqHand system mimics the main advantages of manual pipetting, namely simplicity and versatility, through a unique design of a fully integrated and microfluidic-based platform. In addition, when interfaced with well-established biomedical equipment such as ELISA readers or PCR machines, our platform can form a fully automated lab at significantly lower costs than commercially available devices. Thus, it has the potential to become a standard tool for researchers both in basic and early pharmaceutical/clinical research as well as for clinicians in point-of-care diagnostics. The aim of this Proof-of-Concept proposal is to adapt the AutoLiqHand platform to market needs and optimize it for production in order to make it available to the market.

149 750 €

Start date: 2017-01-01, End date: 2018-06-30

Today’s industry is more vulnerable to cyberattacks than ever. The biggest threat comes from advanced persistent threats that targets the sensitive data of a specific company. Such a threat may come along as an innocuous app that starts its malicious behavior only when the mobile logs into the corporate network. At the same time, such threats can be made undetectable through testing or code analysis. The ERC SPECMATE project has developed a technology named BOXMATE that protects against unexpected changes of app behavior and thus drastically reduces the attack surface of mobile applications. The key idea is to mine app behavior by executing generated tests, systematically exploring the program’s accesses to sensitive data. During production, the app then is placed in a sandbox, which prohibits accesses not seen during testing. This combination of test generation and sandboxing effectively protects against advanced persistent threats. To access sensitive data during production, the app already must do so during testing—where tracing makes it easy to discover and assess. BOXMATE neither does not need to collect user data: All app behavior is assessed during testing already. Finally, BOXMATE requires no knowledge about source or binary code, and thus easily handles arbitrarily obfuscated or obscure third-party apps. BOXMATE is currently being patented worldwide. We want to turn the BOXMATE approach into a full mobile security solution for corporate and end users. This proposal aims at producing a full-fledged prototype that can be demonstrated to potential customers, most notably app vendors and mobile infrastructure providers; as well as developing an adequate marketing strategy exploring and responding to the needs of the market. This proposal is fueled by the principal investigator, Andreas Zeller, one of the world’s leading experts in software test generation and specification mining.

150 000 €

Start date: 2017-09-01, End date: 2019-02-28

Cells respond to external mechanical stimuli through an activation of a cellular mechanism called mechanotransduction. The cellular responses in this mechanism are expressed by a modification in cellular proliferation, migration and differentiation, as well as in a strengthening of their adhesion. Likewise, diseases such as cancer and cardiac dysfunctions are also related to cellular mechanotransduction. Here we propose to take a novel 3D material porous material towards commercial applications. The material serves as a platform for controlling mechanotransduction (e.g. in implant materials) and enables a control of mechanotransduction by mimicking natural 3D cellular environments. Our material contains a novel form of microporous structures represented by micron-sized channels embedded in a polymer matrix of a well-defined stiffness that has been developed within the ERC project CELLINSPIRED. The material guarantees pore interconnectivity independently of pore density and size, a unique feature offered by our fabrication procedure, for which we have applied for a patent (EP 15166793.8, PCT/EP2016/060160). Furthermore, it also provides a large, three-dimensionally controlled cell-surface contact area, such that the mechanical properties of the environment will have large impact on the cells. Our goal in this project is to validate our novel material for cellular applications where mechanotransduction is targeted. The expected outcome of our project is to receive a demonstrator material that (1) has well-defined mechanical properties, porosities and pore dimensions, (2) is biocompatible and can be sterilized, (3) can be fabricated in different levels of complexity, (4) can activate mechanotransduction in cells, and (5) can be fabricated using high-throughput processes. As for commercialization, we aim to license the patent to biomaterials companies involved in applications that range from 3D cell cultures to implant materials.

150 000 €

Start date: 2017-10-01, End date: 2019-03-31